Compare UAA & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UAA | HRMY |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | 14100 | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | N/A | 2020 |
| Metric | UAA | HRMY |
|---|---|---|
| Price | $7.13 | $35.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 16 | 9 |
| Target Price | $6.48 | ★ $44.11 |
| AVG Volume (30 Days) | ★ 7.1M | 856.6K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | N/A | $19.75 |
| Revenue Next Year | $1.57 | $12.88 |
| P/E Ratio | ★ N/A | $65.47 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $4.13 | $25.52 |
| 52 Week High | $8.15 | $40.87 |
| Indicator | UAA | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 60.14 | 52.85 |
| Support Level | $5.47 | $35.05 |
| Resistance Level | $7.50 | $39.07 |
| Average True Range (ATR) | 0.33 | 1.59 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 71.23 | 55.84 |
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 440 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.